UBS Group AG has acquired a significant stake in Australian Clinical Labs Ltd, giving it a 6.41% voting power through over 12.9 million ordinary shares.

This acquisition positions UBS as a substantial shareholder, indicating its significant influence within the company. The acquisition involves various branches and fund management entities of UBS across Australia and Switzerland, reflecting the firm's strategic interest in the healthcare sector.

Investors and analysts should monitor the implications of this stake on Australian Clinical Labs' future operations and market performance. For further insights into AU:ACL stock, resources are available on financial analysis platforms.